An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Effect Of Fluconazole, A Moderate CYP3A4 Inhibitor, On The Single-Dose Pharmacokinetics Of Fesoterodine In Healthy Subjects.

Trial Profile

An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Effect Of Fluconazole, A Moderate CYP3A4 Inhibitor, On The Single-Dose Pharmacokinetics Of Fesoterodine In Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2011

At a glance

  • Drugs Fesoterodine; Fluconazole
  • Indications Overactive bladder
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 31 May 2011 Actual end date changed from Jun 2009 to Jul 2009 as reported by ClinicalTrials.gov.
    • 05 May 2011 Results published in the British Journal of Clinical Pharmacology.
    • 19 Aug 2009 Actual initiation date (May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top